cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.13619396.v3
title: Supplemental tables

description: Supplemental table 1. Results of virological and pathoformological studies of various parts of the central nervous system in sheep with European and Far-Eastern variants of TBEV<br>Supplemental table 2. Clinical observations in the Khabarovsk Territory (Komsomolchky, Lazo, Zabarovsk, Vyazemsky districts, where the first expedition of L.A. Zilber was carried out in 1937) and in Belarus.<br><br>Supplemental table 3. General table of all viruses' particularities considered in the article<br>
DOI: 10.6084/m9.figshare.13619396.v2
title: Supplemental tables

description: Supplemental table 1. Results of virological and pathoformological studies of various parts of the central nervous system in sheep with European and Far-Eastern variants of TBEV<br>Supplemental table 2. Clinical observations in the Khabarovsk Territory (Komsomolchky, Lazo, Zabarovsk, Vyazemsky districts, where the first expedition of L.A. Zilber was carried out in 1937) and in Belarus.<br><br>Supplemental table 3. General table of all viruses' particularities considered in the article<br>
DOI: 10.34810/data72/468
title: 01CO_1.MR.0004.0237.2016.02.04.15.44.11.109375.67144418.IMA
DOI: 10.6084/m9.figshare.14504928
title: Drug–drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H<sub>3</sub> receptor antagonist

description: We evaluated the <i>in vitro</i> drug–drug interaction (DDI) potential of enerisant (TS-091), a histamine H<sub>3</sub> receptor antagonist/inverse agonist, mediated by cytochrome P450 (CYP) and transporters, as well as the pharmacokinetics of enerisant in healthy male subjects.Enerisant did not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 and did not induce CYP1A2, CYP2B6, or CYP3A4. Enerisant inhibited organic cation transporter 2, multidrug and toxin extrusion protein (MATE) 1, and MATE2-K, but not P-glycoprotein (P-gp), breast cancer resistance protein, organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic anion transporter (OAT) 1, or OAT3. Enerisant was a substrate for P-gp, but not for eight other transporters.In healthy male subjects, enerisant was rapidly absorbed after oral administration, and the plasma concentration increased dose-dependently. The urinary excretion of enerisant within 48 h after administration was 64.5% to 89.9% of the dose, indicating that most of the absorbed enerisant was excreted in the urine without being metabolized.Based on the plasma concentrations at the estimated clinical dose, enerisant is unlikely to cause CYP-mediated, clinically relevant DDI. Although the possibility of transporter-mediated, clinically relevant DDI cannot be ruled out, there is little or no risk of side effects. We evaluated the <i>in vitro</i> drug–drug interaction (DDI) potential of enerisant (TS-091), a histamine H<sub>3</sub> receptor antagonist/inverse agonist, mediated by cytochrome P450 (CYP) and transporters, as well as the pharmacokinetics of enerisant in healthy male subjects. Enerisant did not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 and did not induce CYP1A2, CYP2B6, or CYP3A4. Enerisant inhibited organic cation transporter 2, multidrug and toxin extrusion protein (MATE) 1, and MATE2-K, but not P-glycoprotein (P-gp), breast cancer resistance protein, organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic anion transporter (OAT) 1, or OAT3. Enerisant was a substrate for P-gp, but not for eight other transporters. In healthy male subjects, enerisant was rapidly absorbed after oral administration, and the plasma concentration increased dose-dependently. The urinary excretion of enerisant within 48 h after administration was 64.5% to 89.9% of the dose, indicating that most of the absorbed enerisant was excreted in the urine without being metabolized. Based on the plasma concentrations at the estimated clinical dose, enerisant is unlikely to cause CYP-mediated, clinically relevant DDI. Although the possibility of transporter-mediated, clinically relevant DDI cannot be ruled out, there is little or no risk of side effects.
DOI: 10.6084/m9.figshare.14504928.v1
title: Drug–drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H<sub>3</sub> receptor antagonist

description: We evaluated the <i>in vitro</i> drug–drug interaction (DDI) potential of enerisant (TS-091), a histamine H<sub>3</sub> receptor antagonist/inverse agonist, mediated by cytochrome P450 (CYP) and transporters, as well as the pharmacokinetics of enerisant in healthy male subjects.Enerisant did not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 and did not induce CYP1A2, CYP2B6, or CYP3A4. Enerisant inhibited organic cation transporter 2, multidrug and toxin extrusion protein (MATE) 1, and MATE2-K, but not P-glycoprotein (P-gp), breast cancer resistance protein, organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic anion transporter (OAT) 1, or OAT3. Enerisant was a substrate for P-gp, but not for eight other transporters.In healthy male subjects, enerisant was rapidly absorbed after oral administration, and the plasma concentration increased dose-dependently. The urinary excretion of enerisant within 48 h after administration was 64.5% to 89.9% of the dose, indicating that most of the absorbed enerisant was excreted in the urine without being metabolized.Based on the plasma concentrations at the estimated clinical dose, enerisant is unlikely to cause CYP-mediated, clinically relevant DDI. Although the possibility of transporter-mediated, clinically relevant DDI cannot be ruled out, there is little or no risk of side effects. We evaluated the <i>in vitro</i> drug–drug interaction (DDI) potential of enerisant (TS-091), a histamine H<sub>3</sub> receptor antagonist/inverse agonist, mediated by cytochrome P450 (CYP) and transporters, as well as the pharmacokinetics of enerisant in healthy male subjects. Enerisant did not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 and did not induce CYP1A2, CYP2B6, or CYP3A4. Enerisant inhibited organic cation transporter 2, multidrug and toxin extrusion protein (MATE) 1, and MATE2-K, but not P-glycoprotein (P-gp), breast cancer resistance protein, organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic anion transporter (OAT) 1, or OAT3. Enerisant was a substrate for P-gp, but not for eight other transporters. In healthy male subjects, enerisant was rapidly absorbed after oral administration, and the plasma concentration increased dose-dependently. The urinary excretion of enerisant within 48 h after administration was 64.5% to 89.9% of the dose, indicating that most of the absorbed enerisant was excreted in the urine without being metabolized. Based on the plasma concentrations at the estimated clinical dose, enerisant is unlikely to cause CYP-mediated, clinically relevant DDI. Although the possibility of transporter-mediated, clinically relevant DDI cannot be ruled out, there is little or no risk of side effects.
DOI: 10.34810/data72/469
title: 01CO_1.MR.0004.0002.2016.02.04.15.44.11.109375.67133970.IMA
DOI: 10.34810/data72/470
title: 01CO_1.MR.0004.0022.2016.02.04.15.44.11.109375.67134772.IMA
DOI: 10.34810/data72/471
title: 01CO_1.MR.0004.0128.2016.02.04.15.44.11.109375.67139024.IMA
DOI: 10.6084/m9.figshare.15021897
title: Supplementary Material for: Indication for Active Surveillance in the Era of MRI-Targeted Prostate Biopsies

description: <b><i>Introduction:</i></b> Active surveillance (AS) strategies were established to avoid overtreatment of low-risk prostate cancer (PCa) patients. Low tumor volume represents one indication criteria; however, applying this criterion after MRI-targeted prostate biopsies may lead to overestimation of tumor volume; wherefore, patients suitable for AS would be exposed to the risk of overtreatment. <b><i>Methods:</i></b> This retrospective analysis included 318 patients in which PCa was detected by MRI-TRUS fusion prostate biopsy. Classic and extended indication for AS included Gleason 6 and Gleason 3 + 4 cancer, respectively. We assessed the effect of targeted biopsies and temporary rating strategies on eligibility for AS and developed new “composite” algorithms to more accurately assess eligibility for AS. <b><i>Results:</i></b> Forty-four (13.8%) and 60 (18.9%) of the 318 patients qualified for AS according to “classic” and “extended” criteria, respectively. Application of the “composite 1” definition led to AS eligibility of 52 of 248 patients (20.97%) in the classic and of 77 of 248 patients (31.05%) in the “extended” group. <b><i>Conclusions:</i></b> We could demonstrate that classic algorithms led to ineligibility of patients for AS. We propose a new rating algorithm to improve tumor assessment for a more accurate indication for AS.
DOI: 10.34810/data72/472
title: 01CO_1.MR.0004.0035.2016.02.04.15.44.11.109375.67135294.IMA
DOI: 10.34810/data72/473
title: 01CO_1.MR.0004.0043.2016.02.04.15.44.11.109375.67135615.IMA
DOI: 10.34810/data72/474
title: 01CO_1.MR.0004.0235.2016.02.04.15.44.11.109375.67144337.IMA
DOI: 10.6084/m9.figshare.15021912
title: Supplementary Material for: Prodromal Symptoms in Depression: A Systematic Review

description: <b><i>Introduction</i></b>: Appraisal of prodromal symptoms of unipolar depression may complement the traditional cross-sectional approach and provide a longitudinal perspective, according to a staging model of the illness. <b><i>Objective:</i></b> To provide an updated systematic review of clinical studies concerned with prodromal symptoms of unipolar depression, according to PRISMA guidelines. <b><i>Methods:</i></b> Keyword searches were conducted in PubMed, Scopus, and Web of Science. Longitudinal studies on prodromal symptoms and signs in adult patients primarily diagnosed with unipolar depression were selected. Findings were examined separately according to study design (i.e., retrospective or prospective). <b><i>Results:</i></b> Twenty-five studies met the criteria for inclusion in this systematic review. Findings indicate that a distinct prodromal symptomatology – commonly characterized by anxiety, tension, irritability, and somatic complaints – exists before the onset of unipolar depression. The duration of the prodromal phase was highly variable across studies, ranging from less than a month to several years. Prodromal symptoms profile and duration were consistent within individuals across depressive episodes. There was a close relationship between prodromal and residual symptoms of the same depressive episode. <b><i>Conclusions:</i></b> The present systematic review addresses an important, and yet relatively neglected, clinical issue that deserves further investigation and may be of immediate practical value. The findings provide challenging insights into the pathogenesis and course of unipolar depression, which may result in more timely and effective treatment of recurrences. The definition of a prodromal phase in depression would benefit from the joint use of symptom identification, biomarkers, and neuroimaging.
DOI: 10.6084/m9.figshare.15021912.v1
title: Supplementary Material for: Prodromal Symptoms in Depression: A Systematic Review

description: <b><i>Introduction</i></b>: Appraisal of prodromal symptoms of unipolar depression may complement the traditional cross-sectional approach and provide a longitudinal perspective, according to a staging model of the illness. <b><i>Objective:</i></b> To provide an updated systematic review of clinical studies concerned with prodromal symptoms of unipolar depression, according to PRISMA guidelines. <b><i>Methods:</i></b> Keyword searches were conducted in PubMed, Scopus, and Web of Science. Longitudinal studies on prodromal symptoms and signs in adult patients primarily diagnosed with unipolar depression were selected. Findings were examined separately according to study design (i.e., retrospective or prospective). <b><i>Results:</i></b> Twenty-five studies met the criteria for inclusion in this systematic review. Findings indicate that a distinct prodromal symptomatology – commonly characterized by anxiety, tension, irritability, and somatic complaints – exists before the onset of unipolar depression. The duration of the prodromal phase was highly variable across studies, ranging from less than a month to several years. Prodromal symptoms profile and duration were consistent within individuals across depressive episodes. There was a close relationship between prodromal and residual symptoms of the same depressive episode. <b><i>Conclusions:</i></b> The present systematic review addresses an important, and yet relatively neglected, clinical issue that deserves further investigation and may be of immediate practical value. The findings provide challenging insights into the pathogenesis and course of unipolar depression, which may result in more timely and effective treatment of recurrences. The definition of a prodromal phase in depression would benefit from the joint use of symptom identification, biomarkers, and neuroimaging.
DOI: 10.34810/data72/475
title: 01CO_1.MR.0004.0081.2016.02.04.15.44.11.109375.67137139.IMA
DOI: 10.34810/data72/476
title: 01CO_1.MR.0004.0177.2016.02.04.15.44.11.109375.67140989.IMA
DOI: 10.34810/data72/477
title: 01CO_1.MR.0004.0063.2016.02.04.15.44.11.109375.67136417.IMA
DOI: 10.34810/data72/478
title: 01CO_1.MR.0004.0065.2016.02.04.15.44.11.109375.67136497.IMA
DOI: 10.34810/data72/479
title: 01CO_1.MR.0004.0132.2016.02.04.15.44.11.109375.67139184.IMA
DOI: 10.34810/data72/480
title: 01CO_1.MR.0004.0210.2016.02.04.15.44.11.109375.67143335.IMA
DOI: 10.34810/data72/481
title: 02AC_1.MR.0009.0002.2013.03.10.09.04.41.296875.165173352.IMA
DOI: 10.34810/data72/482
title: 02AC_1.MR.0009.0062.2013.03.10.09.04.41.296875.165174432.IMA
DOI: 10.34810/data72/483
title: 02AC_1.MR.0009.0189.2013.03.10.09.04.41.296875.165176725.IMA
DOI: 10.34810/data72/484
title: 02AC_1.MR.0009.0044.2013.03.10.09.04.41.296875.165174108.IMA
DOI: 10.34810/data72/485
title: 02AC_1.MR.0009.0043.2013.03.10.09.04.41.296875.165174090.IMA
DOI: 10.34810/data72/486
title: 02AC_1.MR.0009.0203.2013.03.10.09.04.41.296875.165176977.IMA
DOI: 10.34810/data72/487
title: 02AC_1.MR.0009.0108.2013.03.10.09.04.41.296875.165175260.IMA
DOI: 10.34810/data72/488
title: 02AC_1.MR.0009.0054.2013.03.10.09.04.41.296875.165174288.IMA
DOI: 10.5281/zenodo.5104977
title: 4D-Var data assimilation experiment of the Lorenz 96 model using an adjoint model of a neural network surrogate model

description: These data are the output of the 4D-Var data assimilation experiment of the Lorenz96 model using an adjoint model of a neural network surrogate model.<br> The details are described in Nishizawa (2021).<br>
description: {"references": ["Nishizawa et al. (2021), 4D-Var data assimilation using assimilation using an adjoint model of a neural network sorrogate model. ESSOAr, doi:10.1002/essoar.10507570.1"]}
DOI: 10.34810/data72/489
title: 02AC_1.MR.0009.0107.2013.03.10.09.04.41.296875.165175242.IMA
DOI: 10.34810/data72/490
title: 02AC_1.MR.0009.0068.2013.03.10.09.04.41.296875.165174540.IMA
DOI: 10.34810/data72/491
title: 02AC_1.MR.0009.0031.2013.03.10.09.04.41.296875.165173874.IMA
DOI: 10.6084/m9.figshare.15021984
title: Supplementary Material for: Timing of Nonculprit Percutaneous Coronary Intervention after ST-Elevation Myocardial Infarction

description: <b><i>Introduction:</i></b> Complete revascularization of ST-elevation myocardial infarction (STEMI) patients with multivessel disease (MVD) has recently shown to reduce risk of adverse cardiovascular events, including cardiovascular death. Optimal timing of revascularization of nonculprit lesions remains controversial. We aimed to measure cardiac outcomes related to duration between primary percutaneous coronary intervention (pPCI) of the culprit lesion and staged PCI (sPCI) of nonculprit lesions. <b><i>Methods:</i></b> From a prospectively collected consecutive registry of 3,002 patients treated for STEMI by pPCI, 1,555 patients with MVD requiring sPCI were identified. Patients were placed into quartiles of duration to sPCI: 0–7 days (Q1), 7–22 days (Q2), 22–42 days (Q3), &gt;42 days (Q4), excluding those who had complete revascularization at the index event. Major adverse cardiac events (MACEs) included all-cause mortality, myocardial infarction, target vessel revascularization, and coronary artery bypass surgery. Cox regression and propensity score matching were performed correcting for confounding factors. <b><i>Results:</i></b> The average age at presentation was 65.7 ± 11.5 years. 333 were female (21.4%). Mean time between pPCI and sPCI was 28.3 days (±24.8). Rates of MACE were Q1 - 16.5%, Q2 - 21.2%, Q3 - 25.8%, and Q4 - 30.1% (log-rank &lt;0.001). Following regression analysis, sPCI remained an independent risk factor for MACE (hazard ratio [HR] = 1.226 [95% confidence interval {CI}: 1.129–1.331, <i>p</i> &lt; 0.001]). There was no association between the time interval up to sPCI with all-cause death (HR = 1.022 [95% CI: 0.925–1.129, <i>p</i> = 0.671]). <b><i>Conclusions:</i></b> Patients with MVD are at increased risk of experiencing MACE after revascularization of nonculprit vessels with increasing time delay between pPCI and sPCI.
DOI: 10.6084/m9.figshare.15021984.v1
title: Supplementary Material for: Timing of Nonculprit Percutaneous Coronary Intervention after ST-Elevation Myocardial Infarction

description: <b><i>Introduction:</i></b> Complete revascularization of ST-elevation myocardial infarction (STEMI) patients with multivessel disease (MVD) has recently shown to reduce risk of adverse cardiovascular events, including cardiovascular death. Optimal timing of revascularization of nonculprit lesions remains controversial. We aimed to measure cardiac outcomes related to duration between primary percutaneous coronary intervention (pPCI) of the culprit lesion and staged PCI (sPCI) of nonculprit lesions. <b><i>Methods:</i></b> From a prospectively collected consecutive registry of 3,002 patients treated for STEMI by pPCI, 1,555 patients with MVD requiring sPCI were identified. Patients were placed into quartiles of duration to sPCI: 0–7 days (Q1), 7–22 days (Q2), 22–42 days (Q3), &gt;42 days (Q4), excluding those who had complete revascularization at the index event. Major adverse cardiac events (MACEs) included all-cause mortality, myocardial infarction, target vessel revascularization, and coronary artery bypass surgery. Cox regression and propensity score matching were performed correcting for confounding factors. <b><i>Results:</i></b> The average age at presentation was 65.7 ± 11.5 years. 333 were female (21.4%). Mean time between pPCI and sPCI was 28.3 days (±24.8). Rates of MACE were Q1 - 16.5%, Q2 - 21.2%, Q3 - 25.8%, and Q4 - 30.1% (log-rank &lt;0.001). Following regression analysis, sPCI remained an independent risk factor for MACE (hazard ratio [HR] = 1.226 [95% confidence interval {CI}: 1.129–1.331, <i>p</i> &lt; 0.001]). There was no association between the time interval up to sPCI with all-cause death (HR = 1.022 [95% CI: 0.925–1.129, <i>p</i> = 0.671]). <b><i>Conclusions:</i></b> Patients with MVD are at increased risk of experiencing MACE after revascularization of nonculprit vessels with increasing time delay between pPCI and sPCI.
DOI: 10.34810/data72/492
title: 02AC_1.MR.0009.0161.2013.03.10.09.04.41.296875.165176214.IMA
DOI: 10.34810/data72/493
title: 02AC_1.MR.0009.0188.2013.03.10.09.04.41.296875.165176707.IMA
DOI: 10.34810/data72/494
title: 02AC_1.MR.0009.0013.2013.03.10.09.04.41.296875.165173550.IMA
DOI: 10.26106/cb20-wt30
title: Zooplankton body size is filtered by a thermo-oxygenic niche at a regional scale : data and Rcode - concept
DOI: 10.34810/data72/495
title: 02AC_1.MR.0009.0153.2013.03.10.09.04.41.296875.165176070.IMA
DOI: 10.34810/data72/496
title: 02AC_1.MR.0009.0048.2013.03.10.09.04.41.296875.165174180.IMA
DOI: 10.34810/data72/497
title: 02AC_1.MR.0009.0198.2013.03.10.09.04.41.296875.165176887.IMA
DOI: 10.6084/m9.figshare.14611899
title: Supplementary Material for: Associations Between Suicidal Thoughts and Behaviors and Genetic Liability for Cognitive Performance, Depression, and Risk-taking in a High-risk Sample

description: Medicine
DOI: 10.6084/m9.figshare.14611899.v1
title: Supplementary Material for: Associations Between Suicidal Thoughts and Behaviors and Genetic Liability for Cognitive Performance, Depression, and Risk-taking in a High-risk Sample

description: Medicine
DOI: 10.48370/ofd/lkiujq/qy0ekg
title: HMW_Corydalis_cava_Schweigg._&_Körte_H_8276.jpg

description: :unav
DOI: 10.34810/data72/498
title: 02AC_1.MR.0009.0028.2013.03.10.09.04.41.296875.165173820.IMA
DOI: 10.48370/ofd/lkiujq
title: Kokorycz pusta (Corydalis cava Schweigg. Körte), 8276

description: Herbarium
DOI: 10.48370/ofd/k0cgwy/z45wda
title: HMW_Corydalis_cava_Schweigg._&_Körte_H_6838.jpg

description: :unav
DOI: 10.48370/ofd/k0cgwy
title: Kokorycz pusta (Corydalis cava Schweigg. Körte), 6838

description: Herbarium
DOI: 10.48370/ofd/uty41l/rvb7ud
title: HMW_Corydalis_cava_Schweigg._&_Körte_H_4708.jpg

description: :unav
DOI: 10.48370/ofd/uty41l
title: Kokorycz pusta (Corydalis cava Schweigg. Körte), 4708

description: Herbarium
DOI: 10.48370/ofd/grytmq/4yf1i4
title: HMW_Corydalis_cava_Schweigg._&_Körte_H_9024.jpg

description: :unav
DOI: 10.48370/ofd/grytmq
title: Kokorycz pusta (Corydalis cava Schweigg. Körte), 9024

description: Herbarium
DOI: 10.48370/ofd/libysz/ddcs7e
title: HMW_Corydalis_cava_Schweigg._&_Körte_H_4509.jpg

description: :unav
DOI: 10.48370/ofd/libysz
title: Kokorycz pusta (Corydalis cava Schweigg. Körte), 4509

description: Herbarium
DOI: 10.48370/ofd/2ay5k5/s1cjej
title: HMW_Corydalis_cava_Schweigg._&_Körte_H_0606.jpg

description: :unav
DOI: 10.48370/ofd/2ay5k5
title: Kokorycz pusta (Corydalis cava Schweigg. Körte), 606

description: Herbarium
DOI: 10.34810/data72/499
title: 02AC_1.MR.0009.0240.2013.03.10.09.04.41.296875.165177643.IMA
DOI: 10.48370/ofd/xelxzg/vjeidq
title: HMW_Corydalis_cava_Schweigg._&_Körte_H_0033.jpg

description: :unav
DOI: 10.48370/ofd/xelxzg
title: Kokorycz pusta (Corydalis cava Schweigg. Körte), 33

description: Herbarium
DOI: 10.48370/ofd/auzzju/7wsgrt
title: HMW_Corydalis_cava_Schweigg._&_Körte_H_5562.jpg

description: :unav
DOI: 10.48370/ofd/auzzju
title: Kokorycz pusta (Corydalis cava Schweigg. Körte), 5562

description: Herbarium
DOI: 10.48370/ofd/wk3l1r/nf3vmb
title: HMW_Corydalis_cava_Schweigg._&_Körte_H_5560.jpg

description: :unav
DOI: 10.48370/ofd/wk3l1r
title: Kokorycz pusta (Corydalis cava Schweigg. Körte), 5560

description: Herbarium
DOI: 10.5281/zenodo.5115478
title: Water uptake in wheat

description: A dataset showing the uptake of water by wheat seeds
DOI: 10.5281/zenodo.5115477
title: Water uptake in wheat

description: A dataset showing the uptake of water by wheat seeds
DOI: 10.34810/data72/500
title: 02AC_1.MR.0009.0154.2013.03.10.09.04.41.296875.165176088.IMA
DOI: 10.34810/data72/501
title: 02AC_1.MR.0009.0197.2013.03.10.09.04.41.296875.165176869.IMA
DOI: 10.5281/zenodo.5112604
title: Block Tectonics across Western Tibet and Multi-Millennial Recurrence of Great Earthquakes on the Karakax Fault

description: <strong>Table 1</strong>: Analytical results of <sup>10</sup>Be and <sup>26</sup>Al geochronology and surface-exposure ages at Taersa site along Karakax fault.
DOI: 10.34810/data72/502
title: 02AC_1.MR.0009.0238.2013.03.10.09.04.41.296875.165177607.IMA
DOI: 10.34810/data72/503
title: 02AC_1.MR.0009.0178.2013.03.10.09.04.41.296875.165176527.IMA